You have free access to this content

Cancer

Cover image for Vol. 117 Issue 11

1 June 2011

Volume 117, Issue 11

Pages 2355–2581

  1. CancerScope

    1. Top of page
    2. CancerScope
    3. Commentaries
    4. Editorials
    5. Original Articles
    6. Correspondence
    1. You have free access to this content
    2. You have free access to this content
    3. You have free access to this content
    4. You have free access to this content
  2. Commentaries

    1. Top of page
    2. CancerScope
    3. Commentaries
    4. Editorials
    5. Original Articles
    6. Correspondence
    1. You have free access to this content
      The epidermal growth factor receptor conundrum (pages 2358–2360)

      Jason A. Wilken, Andre T. Baron and Nita J. Maihle

      Version of Record online: 14 DEC 2010 | DOI: 10.1002/cncr.25805

      • original image

      Soluble epidermal growth factor receptor (sEGFR), a cell surface and serum protein derived from an alternately spliced human EGFR transcript, is recognized by 2 therapeutic antibodies approved by the US Food and Drug Administration: cetuximab and panitumumab. Therefore, circulating sEGFR is an unanticipated first target for both of these therapeutic antibodies, adding a new level of complexity to the understanding of EGF receptor biology that should be considered in the design of future clinical studies.

  3. Editorials

    1. Top of page
    2. CancerScope
    3. Commentaries
    4. Editorials
    5. Original Articles
    6. Correspondence
    1. You have free access to this content
  4. Original Articles

    1. Top of page
    2. CancerScope
    3. Commentaries
    4. Editorials
    5. Original Articles
    6. Correspondence
    1. Disease Site

      Gastrointestinal Disease
      You have free access to this content
      Does delay of adjuvant chemotherapy impact survival in patients with resected stage II and III colon adenocarcinoma? (pages 2364–2370)

      Ulas Darda Bayraktar, Emerson Chen, Soley Bayraktar, Laurence R. Sands, Floriano Marchetti, Alberto Jose Montero and Caio Max S. Rocha-Lima

      Version of Record online: 17 DEC 2010 | DOI: 10.1002/cncr.25720

      • original image

      Delay of adjuvant chemotherapy >60 days in patients with stage II and III colon cancer is associated with worse overall survival.

    2. You have free access to this content
      Validation of the seventh edition of the American Joint Committee on Cancer TNM staging system for gastric cancer (pages 2371–2378)

      Hun Jung, Han Hong Lee, Kyo Young Song, Hae Myung Jeon and Cho Hyun Park

      Version of Record online: 11 JAN 2011 | DOI: 10.1002/cncr.25778

      • original image

      The seventh edition of the American Joint Committee on Cancer TNM classification for gastric cancer was considered valid based on the results of the current study. However, the hybrid TNM classification that is comprised of a combination of the seventh edition pT and sixth edition pN classifications should be considered for the next edition.

    3. You have free access to this content
      John Cunningham virus T-antigen expression in anal carcinoma (pages 2379–2385)

      Sonia Ramamoorthy, Bikash Devaraj, Katsumi Miyai, Linda Luo, Yu-Tsueng Liu, C. Richard Boland, Ajay Goel and John M. Carethers

      Version of Record online: 14 DEC 2010 | DOI: 10.1002/cncr.25793

      • original image

      The pathogenesis of anal carcinoma is linked to human papillomavirus (HPV), but this is less clear in HPV-negative anal cancers. John Cunningham virus (JCV) is present in 100% of anal cancers and contains a higher viral load in cancer compared with normal tissue. JCV may play a role in the development of anal cancer.

    4. You have free access to this content
      Induction of MUC5AC mucin by conjugated bile acids in the esophagus involves the phosphatidylinositol 3-kinase/protein kinase C/activator protein-1 pathway (pages 2386–2397)

      Shumei Song, James C. Byrd, Sushovan Guha, Kai-Feng Liu, Dimpy Koul and Robert S. Bresalier

      Version of Record online: 14 DEC 2010 | DOI: 10.1002/cncr.25796

      • original image
      • original image
      • original image
      • original image
      • original image
      • original image

      Conjugated bile acids in the bile refluxate contribute to mucin 5AC (MUC5AC) induction in the esophagus. This occurs at the level of transcription, and involves activation of the phosphatidylinositol 3-kinase/protein kinase C/activator protein-1 (PI3K/AKT/AP-1) pathway.

    5. You have free access to this content
      Metabolic factors and the risk of colorectal cancer in 580,000 men and women in the metabolic syndrome and cancer project (Me-Can) (pages 2398–2407)

      Tanja Stocks, Annekatrin Lukanova, Tone Bjørge, Hanno Ulmer, Jonas Manjer, Martin Almquist, Hans Concin, Anders Engeland, Göran Hallmans, Gabriele Nagel, Steinar Tretli, Marit B. Veierød, Håkan Jonsson, Pär Stattin and for the Metabolic Syndrome Cancer Project (Me-Can) Group

      Version of Record online: 17 DEC 2010 | DOI: 10.1002/cncr.25772

      • original image
      • original image

      Factors in the metabolic syndrome have been related to an increased risk of colorectal cancer, but the association has not been assessed in detail. In this large, prospective study, the authors observed that a high score of metabolic factors combined, and some factors alone, were related to an increased risk of colorectal cancer, but there was no interaction between the metabolic factors and risk.

    6. You have free access to this content
      Epidermal growth factor down-regulates the expression of neutrophil gelatinase-associated lipocalin (NGAL) through E-cadherin in pancreatic cancer cells (pages 2408–2418)

      Zhimin Tong, Subhankar Chakraborty, Bokyung Sung, Pooja Koolwal, Sukhwinder Kaur, Bharat B. Aggarwal, Sendurai A. Mani, Robert S. Bresalier, Surinder K. Batra and Sushovan Guha

      Version of Record online: 29 DEC 2010 | DOI: 10.1002/cncr.25803

      • original image
      • original image
      • original image
      • original image
      • original image
      • original image

      The current study indicated that the epidermal growth factor-epidermal growth factor receptor signaling pathway down-regulates the expression of neutrophil gelatinase-associated lipocalin (NGAL) in pancreatic cancer cells. Thus, the findings illustrate a novel mechanism by which E-cadherin and NGAL expression are lost in pancreatic cancer.

    7. Genitourinary Disease
      You have free access to this content
      Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy : A phase 2 study of the department of defense prostate cancer clinical trials consortium (pages 2419–2425)

      Andrea L. Harzstark, Jonathan E. Rosenberg, Vivian K. Weinberg, Jeremy Sharib, Charles J. Ryan, David C. Smith, Lance C. Pagliaro, Tomasz M. Beer, Glenn Liu and Eric J. Small

      Version of Record online: 29 DEC 2010 | DOI: 10.1002/cncr.25810

      • original image
      • original image
      • original image

      A multicenter phase 2 study of the combination of ixabepilone and mitoxantrone with prednisone was performed in patients with metastatic castration-resistant prostate cancer who had progressed during or after taxane-based chemotherapy. Forty-five percent of patients experienced confirmed ≥50% prostate-specific antigen declines, and 22% of patients with objective disease experienced objective responses; toxicity was acceptable, although dosing with pegfilgrastim was required.

    8. You have free access to this content
      Prognostic factors in male urethral cancer (pages 2426–2434)

      Farhang Rabbani

      Version of Record online: 14 DEC 2010 | DOI: 10.1002/cncr.25787

      • original image
      • original image

      Age, grade, TNM stage, histology, and extent of surgery were predictive of overall and cancer-specific survival in male urethral cancer. Surgery had a better outcome than radiation for stage T2-T4 nonmetastatic disease.

    9. Head and Neck Disease
      You have free access to this content
      The role of technetium-99m methoxyisobutyl isonitrile scintigraphy in predicting the therapeutic effect of chemotherapy against nasopharyngeal carcinoma (pages 2435–2441)

      Xiao Shen Wang, Ying Jian Zhang, Xiao Lan Liu, Zheng Rong Zhou, Chao Su Hu and Avraham Eisbruch

      Version of Record online: 14 DEC 2010 | DOI: 10.1002/cncr.25802

      • original image
      • original image

      In this study, patients with nasopharyngeal carcinoma (NPC) who had negative technetium-99m methoxyisobutyl isonitrile (99mTc-MIBI) accumulation were resistant to combined chemotherapy with 5-fluorouracil and cisplatin (5-FU/DDP). The results indicated that 99mTc-MIBI imaging in patients with NPC can predict tumor response to combined 5-FU/DDP chemotherapy and may help in the selection of patients for induction chemotherapy.

    10. Hematologic Malignancies
      You have free access to this content
      Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma (pages 2442–2451)

      Robert A. Baiocchi, Lapo Alinari, Mark E. Lustberg, Thomas S. Lin, Pierluigi Porcu, Xiaobai Li, Jeffrey S. Johnston, John C. Byrd and Kristie A. Blum

      Version of Record online: 14 DEC 2010 | DOI: 10.1002/cncr.25792

      • original image
      • original image
      • original image
      • original image

      Encouraging preclinical data demonstrating that bortezomib in combination with rituximab (R-bortezomib) leads to synergistic apoptosis in non-Hodgkin lymphoma provided justification for a phase 2 combination trial of R-bortezomib in patients with relapsed mantle cell and follicular lymphoma, who had response rates of 29% and 55%, respectively. However, grade 3 neurotoxicity that occurred in 52% of patients enrolled on the trial limited prolonged dosing with this combination.

    11. You have free access to this content
      A comparison of the efficacy and safety of oral and intravenous fludarabine in chronic lymphocytic leukemia in the LRF CLL4 trial (pages 2452–2460)

      Claire E. Dearden, Sue Richards, Monica Else, Daniel Catovsky and Peter Hillmen

      Version of Record online: 14 DEC 2010 | DOI: 10.1002/cncr.25776

      • original image

      Although the retrospectively assessed data from the LRF CLL4 trial suggest no important difference in the effectiveness of oral compared with intravenous fludarabine, randomized trials are needed to reliably evaluate this comparison, particularly in combination with rituximab. Meanwhile, it is important to monitor compliance and gastrointestinal side effects with the oral route and to switch to intravenous therapy if a reduced dose is being received.

    12. You have free access to this content
      Incidence of gastric involvement in patients with nongastrointestinal extranodal marginal zone lymphoma (pages 2461–2466)

      Ali Mazloom, Alma Rodriguez, Chul S. Ha, L. Jeffery Medeiros, Christine Wogan, Ferial Shihadeh, Pamela Allen, Nathan Fowler and Bouthaina Dabaja

      Version of Record online: 14 DEC 2010 | DOI: 10.1002/cncr.25808

      Routine esophagogastroduodenoscopy is recommended for patients with extragastrointestinal marginal zone lymphoma. This is especially true for those at increased risk of gastric involvement, namely female patients, those with a high International Prognostic Index or β2-microglobulin level, those with Helicobacter pylori infection, or those with primary aerodigestive mucosa/glandular tissue involvement.

    13. You have free access to this content
      Translocation t(14;18)/IGH-BCL2 in gastrointestinal follicular lymphoma : Correlation with clinicopathologic features in 48 patients (pages 2467–2477)

      Shunichi Yanai, Shotaro Nakamura, Morishige Takeshita, Kouhei Fujita, Minako Hirahashi, Keisuke Kawasaki, Koichi Kurahara, Yuji Sakai and Takayuki Matsumoto

      Version of Record online: 29 DEC 2010 | DOI: 10.1002/cncr.25811

      • original image
      • original image
      • original image

      The authors retrospectively investigated the clinicopathologic and molecular features of 48 patients with gastrointestinal follicular lymphoma. Chromosomal translocation t(14;18)(q32;q21) involving the immunoglobulin heavy gene (IGH) and the BCL2 gene(IGH-BCL2) was detected in 81% of patients, and the results indicated that this translocation may be a predictor of an adverse clinical disease course.

    14. Hepatobiliary Disease
      You have free access to this content
      V-CLIP: Integrating plasma vascular endothelial growth factor into a new scoring system to stratify patients with advanced hepatocellular carcinoma for clinical trials (pages 2478–2488)

      Ahmed O. Kaseb, Manal M. Hassan, E Lin, Lianchun Xiao, Vikas Kumar, Priyanka Pathak, Richard Lozano, Asif Rashid, James L. Abbruzzese and Jeffrey S. Morris

      Version of Record online: 14 DEC 2010 | DOI: 10.1002/cncr.25791

      • original image

      After identifying an optimal vascular endothelial growth factor (VEGF) cutpoint of 450 pg/mL and validating the Cancer of the Liver Italian Program (CLIP) scoring system in hepatocellular carcinoma patients, VEGF was added to the CLIP score. The resultant scoring system enabled a more precise prediction of prognosis, suggesting a correlation between VEGF and survival in hepatocellular carcinoma patients.

    15. Melanoma
      You have free access to this content
      Clinical and histologic factors associated with melanoma thickness in New Zealand Europeans, Maori, and Pacific peoples (pages 2489–2498)

      Mary Jane Sneyd and Brian Cox

      Version of Record online: 14 DEC 2010 | DOI: 10.1002/cncr.25795

      • original image
      • original image
      • original image

      Differences in melanoma thickness among ethnic groups in New Zealand were not explained fully by tumor subtype, site, or extent of disease. The current results indicated that the thicker melanomas in darker skinned populations probably can be accounted for in part by more aggressive lesions.

    16. Neuro-Oncology
      You have free access to this content
      Additive effect on survival of Raf kinase inhibitor protein and signal transducer and activator of transcription 3 in high-grade glioma (pages 2499–2504)

      Judith Maresch, Peter Birner, Mikhail Zakharinov, Kalina Toumangelova-Uzeir, Sevdalin Natchev and Marin Guentchev

      Version of Record online: 14 DEC 2010 | DOI: 10.1002/cncr.25799

      • original image
      • original image
      • original image

      The purpose of this study was to show that Raf kinase inhibitor protein expression and lack of signal transducer and activator of transcription 3 phosphorylation have a cumulative prognostic impact on high-grade glioma patients exceeding the prognostic relevance of each single marker. The results of the study represented the first human evidence of an additive effect of 2 distinct signaling pathways in high-grade glioma.

    17. You have free access to this content
      Presentation, patterns of care, and survival in patients with brain metastases : What has changed in the last 20 years? (pages 2505–2512)

      Carsten Nieder, Oddvar Spanne, Minesh P. Mehta, Anca L. Grosu and Hans Geinitz

      Version of Record online: 14 DEC 2010 | DOI: 10.1002/cncr.25707

      • original image
      • original image
      • original image
      • original image

      Patients with brain metastases are now managed on a much more individualized basis, apparently resulting in clinically relevant survival improvement in those with favorable prognostic features.

    18. Sarcoma
      You have free access to this content
      High-risk extracranial chondrosarcoma : Long-term results of surgery and radiation therapy (pages 2513–2519)

      Jayant Sastri Goda, Peter C. Ferguson, Brian O'Sullivan, Charles N. Catton, Anthony M. Griffin, Jay S. Wunder, Robert S. Bell, Rita A. Kandel and Peter W. Chung

      Version of Record online: 18 JAN 2011 | DOI: 10.1002/cncr.25806

      • original image
      • original image
      • original image

      High-risk extracranial chondrosarcomas treated with combined surgery and radiation therapy have excellent long-term local control.

    19. Discipline

      Disparities Research
      You have free access to this content
      Variation in quality of care among older men with localized prostate cancer (pages 2520–2529)

      Ravishankar Jayadevappa, Sumedha Chhatre, Jerry C. Johnson and S. Bruce Malkowicz

      Version of Record online: 14 DEC 2010 | DOI: 10.1002/cncr.25812

      • original image

      Racial and ethnic disparities in outcome among men with localized prostate cancer were associated with process-of-care measures. The current study indicated that there is an opportunity to reduce these disparities by addressing such process-of-care measures.

    20. You have free access to this content
      Racial differences in the presentation and outcomes of diffuse large B-cell lymphoma in the United States (pages 2530–2540)

      Pareen J. Shenoy, Neha Malik, Ajay Nooka, Rajni Sinha, Kevin C. Ward, Otis W. Brawley, Joseph Lipscomb and Christopher R. Flowers

      Version of Record online: 22 DEC 2010 | DOI: 10.1002/cncr.25765

      • original image
      • original image
      • original image

      This paper evaluates the United States, Surveillance, Epidemiology, and End Results cancer registry data to determine the differences in the incidence rates and survival of diffuse large B-cell lymphoma (DLBCL) across racial groups. The results show that black patients with DLBCL present at younger age, more advanced stage, and have inferior survival.

    21. Pediatric Oncology
      You have free access to this content
      Tumor volume and patient weight as predictors of outcome in children with intermediate risk rhabdomyosarcoma : A report from the children's oncology group (pages 2541–2550)

      David A. Rodeberg, Julie A. Stoner, Norbert Garcia-Henriquez, R. Lor Randall, Sheri L. Spunt, Carola A. Arndt, Simon Kao, Charles N. Paidas, Lynn Million and Douglas S. Hawkins

      Version of Record online: 14 DEC 2010 | DOI: 10.1002/cncr.25719

      • original image
      • original image

      Factors that had the strongest association with event-free survival in children with rhabdomyosarcoma were tumor volume, patient weight, and histology. On the basis of regression modeling, tumor volume and patient weight were superior predictors of outcome compared with tumor size and patient age in children with intermediate-risk rhabdomyosarcoma.

    22. Symptom Control and Palliative Care
      You have free access to this content
      Novel approach using antimicrobial catheters to improve the management of central line-associated bloodstream infections in cancer patients (pages 2551–2558)

      Anne-Marie Chaftari, Christelle Kassis, Hiba El Issa, Iba Al Wohoush, Ying Jiang, Gopikishan Rangaraj, Brenda Caillouet, S. Egbert Pravinkumar, Ray Y. Hachem and Issam I. Raad

      Version of Record online: 14 DEC 2010 | DOI: 10.1002/cncr.25807

      • original image
      • original image

      Exchanging central venous catheters (CVCs) for minocycline- and rifampin-coated CVCs in cancer patients with central line-associated bloodstream infections may improve the overall response rate and decrease the risk of mechanical failure, disease recurrence, and infection-related mortality.

    23. You have free access to this content
      Fatigue, vitality, sleep, and neurocognitive functioning in adult survivors of childhood cancer : A report from the childhood cancer survivor study (pages 2559–2568)

      Nancy R. Clanton, James L. Klosky, Chenghong Li, Neelam Jain, Deo Kumar Srivastava, Daniel Mulrooney, Lonnie Zeltzer, Marilyn Stovall, Leslie L. Robison and Kevin R. Krull

      Version of Record online: 11 APR 2011 | DOI: 10.1002/cncr.25797

      Neurocognitive function in long-term survivors of childhood cancer appears particularly vulnerable to the effects of fatigue and sleep disruption. These findings suggest sleep hygiene should be emphasized among survivors of childhood cancer, as they may provide an additional mechanism for intervention to improve neurocognitive outcomes.

    24. You have free access to this content
      How does patient-clinician information engagement influence self-reported cancer-related problems? : Findings from a longitudinal analysis (pages 2569–2576)

      Andy S. L. Tan, Angel Bourgoin, Stacy W. Gray, Katrina Armstrong and Robert C. Hornik

      Version of Record online: 10 JAN 2011 | DOI: 10.1002/cncr.25804

      • original image

      In this longitudinal study among cancer patients in Pennsylvania, increased patient-clinician information engagement predicted more self-reported symptoms and issues that were related to their cancer diagnosis and treatment. This pattern was observed among those patients who had more symptoms at baseline. Increased discussion of cancer information with physicians may maintain the salience of physical and psychosocial symptoms in cancer survivors' minds over time.

  5. Correspondence

    1. Top of page
    2. CancerScope
    3. Commentaries
    4. Editorials
    5. Original Articles
    6. Correspondence
    1. You have free access to this content
    2. You have free access to this content
    3. You have free access to this content
      Detection of minimal residual disease in blood and bone marrow in early stage breast cancer (page 2578)

      Jang-Fang Kuo, Wea-Long Lin and Chih-Ping Han

      Version of Record online: 22 MAR 2011 | DOI: 10.1002/cncr.26089

      Corrected by:

      Erratum: Erratum: Detection of minimal residual disease in blood and bone marrow in early stage breast cancer

      Vol. 118, Issue 9, 2561, Version of Record online: 31 AUG 2011

    4. You have free access to this content
    5. You have free access to this content
    6. You have free access to this content

SEARCH

SEARCH BY CITATION